Rice Hall James & Associates, LLC Fate Therapeutics Inc Transaction History

Rice Hall James & Associates, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 27, 2023	SELL	$9.86 - $23.83 $61,940 - $149,700	-6,282 Reduced 2.87%	212,864 $0
Q3 2022 Nov 01, 2022	SELL	$21.04 - $36.06 $1.13 Million - $1.94 Million	-53,887 Reduced 19.74%	219,146 $4.91 Million
Q2 2022 Aug 08, 2022	BUY	$17.78 - $42.39 $482,140 - $1.15 Million	27,117 Added 11.03%	273,033 $6.77 Million
Q1 2022 May 05, 2022	SELL	$29.67 - $60.28 $127,462 - $258,962	-4,296 Reduced 1.72%	245,916 $9.53 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $504,424 - $678,400	-10,544 Reduced 4.04%	250,212 $14.6 Million
Q3 2021 Nov 09, 2021	SELL	$59.27 - $95.73 $4.43 Million - $7.15 Million	-74,671 Reduced 22.26%	260,756 $15.5 Million
Q2 2021 Jul 29, 2021	SELL	$67.25 - $92.52 $3.29 Million - $4.53 Million	-48,935 Reduced 12.73%	335,427 $29.1 Million
Q1 2021 May 14, 2021	SELL	$72.16 - $117.4 $213,954 - $348,091	-2,965 Reduced 0.77%	384,362 $31.7 Million
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $2.3 Million - $6.11 Million	60,483 Added 18.51%	387,327 $35.2 Million
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $9.94 Million - $13.2 Million	326,844 New	326,844 $13.1 Million

167

101M

41.3K

15.9K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $91.2M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

Stay updated on Rice Hall James & Associates, LLC with notifications on news.